Physicians Financial Services Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,411 shares of the company’s stock after purchasing an additional 1,810 shares during the period. Johnson & Johnson makes up about 2.2% of Physicians Financial Services Inc.’s holdings, making the stock its 8th biggest position. Physicians Financial Services Inc.’s holdings in Johnson & Johnson were worth $3,995,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Altshuler Shaham Ltd purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $35,000. Lake Point Wealth Management boosted its stake in shares of Johnson & Johnson by 144.4% during the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after acquiring an additional 169 shares in the last quarter. SeaBridge Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 160.0% during the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares in the last quarter. Lion Street Advisors LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $45,000. Finally, Joseph P. Lucia & Associates LLC boosted its stake in shares of Johnson & Johnson by 50.8% during the 1st quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock worth $49,000 after acquiring an additional 126 shares in the last quarter. Institutional investors own 68.44% of the company’s stock.
Several equities research analysts have recently commented on JNJ shares. UBS Group lowered Johnson & Johnson from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $163.00 to $160.00 in a research note on Tuesday, April 28th. Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the stock from $161.00 to $164.00 in a research note on Monday, July 20th. Wells Fargo & Co raised Johnson & Johnson to a “hold” rating in a research note on Wednesday, April 22nd. Raymond James upped their target price on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $168.00 target price on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $163.38.
Shares of Johnson & Johnson stock opened at $145.76 on Friday. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The firm has a market cap of $383.76 billion, a PE ratio of 21.31, a P/E/G ratio of 3.23 and a beta of 0.69. The business’s fifty day moving average is $144.04 and its two-hundred day moving average is $144.14. The company has a quick ratio of 1.05, a current ratio of 1.25 and a debt-to-equity ratio of 0.40.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The company had revenue of $18.34 billion for the quarter, compared to analyst estimates of $17.73 billion. During the same quarter in the prior year, the company posted $2.58 EPS. The business’s revenue for the quarter was down 10.8% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 7.85 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date is Monday, August 24th. Johnson & Johnson’s dividend payout ratio is presently 46.54%.
In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the transaction, the executive vice president now owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.27% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Are sell-side analysts objective?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.